INO-5412 / Inovio - LARVOL DELTA

INOVIO and Akeso Announce Clinical Collaboration to Advance Novel Combination Therapy for Glioblastoma (GBM) (Inovio Press Release) - "Collaboration will evaluate INOVIO's INO-5412 (INO-5401 plus INO-9012) in combination with Akeso's cadonilimab as a potential treatment for glioblastoma (GBM), the most common and aggressive form of brain cancer...The combination therapy will be studied as a part of INSIGhT, the innovative Phase 2 adaptive platform trial sponsored by the Dana-Farber Cancer Institute and conducted with Mass General Brigham Cancer Care, Inc., which is designed to quickly and efficiently find new treatments for GBM. Dosing in the combination therapy trial is expected to begin in the second half of 2026."

Trial status • Glioblastoma

Akeso, Inc…and INOVIO…announced that they have entered into a clinical trial collaboration and supply agreement to evaluate cadonilimab, Akeso’s first-in-class PD-1/CTLA-4 bispecific antibody, in combination with INO-5412, INOVIO’s DNA immunotherapy candidate, for the potential treatment of GBM. (PRNewswire) - "The combination therapy will be studied as a part of INSIGhT, the innovative Phase II adaptive platform trial sponsored by the Dana-Farber Cancer Institute and conducted with Mass General Brigham Cancer Care, Inc., which is designed to quickly and efficiently find new treatments for GBM. Dosing in the combination therapy trial is expected to begin in the second half of 2026....Under the terms of the agreement, INOVIO and Akeso will provide support for the INSIGhT study, including supplying their respective therapeutic products, while the investigative sponsors will oversee the day-to-day clinical operations."

Commercial • Glioblastoma